It has been reported as a prognostic marker for oral squamous cell carcinoma (Huang SN et al., 2020), metastatic breast cancer (Liu et al., 2021), pancreatic cancer (Chen et al., 2022), and glioma (Lvu et al., 2020), and down-regulated F2RL2 expression has been detected in rectal cancer (Supiot et al., 2013). Here, F2RL2 is linked to familial pancreatic carcinoma.